Nu 8 - Lakewood Amedex
Alternative Names: Nu-8Latest Information Update: 28 Jul 2024
At a glance
- Originator Oligos Etc.
- Developer Lakewood Amedex
- Class Amines; Anti-infectives; Anti-inflammatories; Antibacterials; Antifibrotics; Antifungals; Furans; Nucleotides; Pyrimidines; Small molecules
- Mechanism of Action Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stomatitis
- No development reported Cystic fibrosis; Urinary tract infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Urinary-tract-infections in USA (Infusion)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (Inhalation, Aerosol)
- 19 Aug 2022 Preclinical trials in Stomatitis in USA (unspecified route), as of August 2022 (Lakewood Amedex pipeline, August 2022)